has reached an important milestone in identifying the Prostate Secretory Protein of 94 amino acids (PSP94) binding protein.
In a previous peer-reviewed publication, Procyon's collaborating scientists demonstrated that pre-treatment blood measurements of bound and free PSP94 can accurately separate prostate cancer patients treated with curative intent radiotherapy into "good" and "bad" prognostic groups.